Skip to main content

Advertisement

Table 4 The Cox proportional hazards model of cancer specific survivalin synchronous and metachronous mRCC group

From: Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis

  Synchronous mRCC (N = 144 / EVENT = 123) Metachronous mRCC (N = 70 / EVENT = 59)
Univariable Multivariable Univariable Multivariable
Hazard ratio
(95% CI)
P-value Hazard ratio
(95% CI)
P-value Hazard ratio
(95% CI)
P-value Hazard ratio
(95% CI)
P-value
Risk group Intermediate 1     1   1  
poor 2.377 (1.591–3.553) <.0001    3.536 (1.332–9.390) 0.0113 3.536 (1.332–9.390) 0.0113
Therapy IT 1     1    
TT 0.854 (0.590–1.237) 0.4041    0.725 (0.428–1.228) 0.2312   
Treatment Free interval ≥1 yr 1     1    
< 1 yr 1.465 (0.714–3.009) 0.2978    1.918 (1.089–3.378) 0.0241   
Gender Male 1     1    
Female 1.185 (0.758–1.854) 0.4557    1.313 (0.768–2.246) 0.3200   
Age (year)   1.002 (0.985–1.019) 0.8225    0.986 (0.959–1.013) 0.3126   
Anemia Normal 1     1    
Hb < 13.5(male)/12.0(Female) 1.555 (0.977–2.475) 0.0626    0.738 (0.372–1.464) 0.3841   
Hypercalcemia Normal 1   1   1    
> 10 mg/dL or 2.5 mmol/L 2.118 (1.297–3.460) 0.0027 2.164 (1.307–3.584) 0.0027 0.948 (0.429–2.098) 0.8956   
Neutrophilia Normal 1   1   1    
< 1500 or > 7500 2.595 (1.589–4.238) 0.0001 2.655 (1.601–4.405) 0.0002 1.296 (0.631–2.661) 0.4798   
Elevated LDH Normal 1     1    
1.5 X ULN 1.482 (0.943–2.329) 0.0883    1.491 (0.661–3.365) 0.3357   
KPS >  80 1        
≤ 80 1.185 (0.375–3.742) 0.7730       
Thrombocytosis Normal 1     1    
> 400 K 2.494 (1.437–4.327) 0.0012    1.941 (0.592–6.363) 0.2734